Kestra Advisory Services’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$158K Hold
49,811
– – ﹤0.01% 3304
2026
Q2
$194K Sell
49,811
-11,930
-19% -$44.4K ﹤0.01% 3110
2026
Q1
$236K Buy
61,741
+50,191
+435% +$200K ﹤0.01% 2828
2025
Q4
$43.2K Sell
11,550
-380
-3% -$1.25K ﹤0.01% 4032
2025
Q3
$24K Hold
11,930
– – ﹤0.01% 2879
2025
Q2
$20.9K Hold
11,930
– – ﹤0.01% 2798
2025
Q1
$16.2K Hold
11,930
– – ﹤0.01% 2696
2024
Q4
$45.3K Hold
11,930
– – ﹤0.01% 2614
2024
Q3
$32.2K Buy
+11,930
New +$33K ﹤0.01% 2518
2024
Q1
– Sell
-8,800
Closed -$60.5K – 2520
2023
Q4
$60.5K Buy
8,800
+6,700
+319% +$56.2K ﹤0.01% 2210
2023
Q3
$13.2K Hold
2,100
– – ﹤0.01% 2092
2023
Q2
$17.4K Buy
2,100
+1,000
+91% +$8.19K ﹤0.01% 2082
2023
Q1
$4.84K Hold
1,100
– – ﹤0.01% 2041
2022
Q4
$6.49K Hold
1,100
– – ﹤0.01% 2240
2022
Q3
$8K Hold
1,100
– – ﹤0.01% 2085
2022
Q2
$16K Buy
+1,100
New +$23.1K ﹤0.01% 2097

Other funds holding SABS

Kestra Advisory Services's SABS Position: Q3 2026 in Review

Kestra Advisory Services held its SAB Biotherapeutics (SABS) position steady in Q3 2026 at 49,811 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #3304.

Kestra Advisory Services first reported a position in SABS in Q2 2022 and has held it in 16 quarters since. The position peaked at $236K in Q1 2026. 100 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Kestra Advisory Services held 49,811 shares of SAB Biotherapeutics worth $158K as of Q3 2026.
  • Kestra Advisory Services left its SAB Biotherapeutics share count unchanged in Q3 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #3304 holding.
  • Kestra Advisory Services first reported a position in SAB Biotherapeutics in Q2 2022 and has held it in 16 quarters since.
  • Kestra Advisory Services's SAB Biotherapeutics position peaked at $236K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.